Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.20.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2019
Dec. 31, 2018
Current assets    
Cash $ 681,759 $ 89
Prepaid expenses 9,054 12,991
Total current assets 690,813 13,080
Total Assets 690,813 13,080
Current liabilities    
Accounts payable 213,880 191,714
Accrued expenses 419,607 421,000
Accrued interest payable 674,041 537,118
Related party payables 905,443 1,423,984
Derivative liabilities 60,650
Common stock subscriptions payable 79,624 1,271
Preferred stock subscriptions payable 1,000,000
Notes payable - current - related parties * Includes unamortized debt discount related to detached warrants of $8,656 and $8,074 at December 31, 2019 and December 31, 2018, respectively 760,886 697,770
Notes payable - current - non-related parties * Includes unamortized debt discount related to convertible notes of none and $5,920 at December 31,2019 and December 31, 2018, respectively 169,574 163,654
Total current liabilities 4,283,934 3,436,511
Total Liabilities 4,283,934 3,436,511
Stockholders' Deficit    
Preferred stock value
Common stock, $0.00001 par value; 800,000,000 shares authorized; 214,626,540 and 109,409,930 shares issued and outstanding as of December 31, 2019 and December 31, 2018, respectively 2,146 1,172
Additional paid-in capital 15,969,311 14,887,804
Accumulated deficit (19,511,168) (18,262,136)
Total Transbiotec, Inc. stockholders' deficit (3,539,711) (3,373,146)
Noncontrolling interest (53,410) (50,285)
Total Stockholders' Deficit (3,593,121) (3,423,431)
Total Liabilities and Stockholders' Deficit 690,813 13,080
Series A Convertible Preferred stock [Member]    
Stockholders' Deficit    
Preferred stock value $ 14
Series A-1 Convertible Preferred stock [Member]    
Stockholders' Deficit    
Preferred stock value